Transgenic animal models of neurodegeneration based on human genetic studies
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
The identification of genes linked to neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD) and Parkinson’s disease (PD) has led to the development of animal models for studying mechanism and evaluating potential therapies. None of the transgenic models developed based on disease-associated genes have been able to fully recapitulate the behavioral and pathological features of the corresponding disease. However, there has been enormous progress made in identifying potential therapeutic targets and understanding some of the common mechanisms of neurodegeneration. In this review, we will discuss transgenic animal models for AD, ALS, HD and PD that are based on human genetic studies. All of the diseases discussed have active or complete clinical trials for experimental treatments that benefited from transgenic models of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
Shimura, H., Hattori, N., Kubo, S.-I., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., et al. (2000) · Nature Genetics · doi:10.1038/77060 · Cited by 2,024 · cited 2×
“Parkin has an E3 ubiquitin-protein ligase activity (Shimura et al. 2000) and targets proteins for degradation by the proteosome (Zhang et al.”
Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin
Clark, I. E., Dodson, M. W., Jiang, C., Cao, J. H., Huh, J. R., Seol, J. H., Yoo, S. J., Hay, B. A., & Guo, M. (2006) · Nature · doi:10.1038/nature04779 · Cited by 1,788 · cited 2×
“Studies in Drosophilia have found that PINK1 and Parkin are involved in a common pathway important for mitochondrial function and morphology (Clark et al. 2006; Park et al. 2006, 2009; Deng et al. 2008; Kim et al. 2008; Yang et al. 2008).”
Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System
Abeliovich, A., Schmitz, Y., Fariñas, I., Choi-Lundberg, D., Ho, W.-H., Castillo, P. E., Shinsky, N., Verdugo, J. M. G., Armanini, M., Ryan, A., et al. (2000) · Neuron · doi:10.1016/s0896-6273(00)80886-7 · Cited by 1,722
Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin
Park, J., Lee, S. B., Lee, S., Kim, Y., Song, S., Kim, S., Bae, E., Kim, J., Shong, M., Kim, J.-M., et al. (2006) · Nature · doi:10.1038/nature04788 · Cited by 1,705 · cited 1×
“Studies in Drosophilia have found that PINK1 and Parkin are involved in a common pathway important for mitochondrial function and morphology (Clark et al. 2006; Park et al. 2006, 2009; Deng et al. 2008; Kim et al. 2008; Yang et al. 2008).”
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611 · cited 2×
“The TAPP mice exhibited increased NFTs in the limbic system and olfactory cortex (Lewis et al. 2001).”
Bender, A., Krishnan, K. J., Morris, C. M., Taylor, G. A., Reeve, A. K., Perry, R. H., Jaros, E., Hersheson, J. S., Betts, J., Klopstock, T., et al. (2006) · Nature Genetics · doi:10.1038/ng1769 · Cited by 1,570 · cited 2×
“Point mutations in the PTEN-induced kinase or PINK1 gene, a putative mitochondrial kinase at the PARK6 locus, are the second most frequently occurring cause of autosomal recessively inherited early-onset PD (Valente et al. 2001,2004; Hatano et al. 2004; Rogaeva et al. 2004; Rohe et al. 2004; Bonifati et al. 2005; Bend…”
TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis
Kabashi, E., Valdmanis, P. N., Dion, P., Spiegelman, D., McConkey, B. J., Velde, C. V., Bouchard, J.-P., Lacomblez, L., Pochigaeva, K., Salachas, F., et al. (2008) · Nature Genetics · doi:10.1038/ng.132 · Cited by 1,544 · cited 2×
“…protein (TARDBP; ALS10) Several studies have confirmed that mutations in the TARDBP gene are associated with familial ALS10-type forms of ALS (Kabashi et al. 2008; Kuhnlein et al. 2008; Rutherford et al. 2008; Sreedharan et al. 2008; Van Deerlin et al. 2008; Corrado et al. 2009) and sporadic…”
Mullan, M., Crawford, F., Axelman, K., Houlden, H., Lilius, L., Winblad, B., & Lannfelt, L. (1992) · Nature Genetics · doi:10.1038/ng0892-345 · Cited by 1,513 · cited 2×
“Analysis of Swedish families with early onset AD identified a double mutation (K670N and M671L) in the APP gene (Mullan et al. 1992).”
Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.-H., Mistl, C., Rothacher, S., Ledermann, B., Bürki, K., Frey, P., Paganetti, P. A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13287 · Cited by 1,507
Bruijn, L. I., Becher, M. W., Lee, M. K., Anderson, K. L., Jenkins, N. A., Copeland, N. G., Sisodia, S. S., Rothstein, J. D., Borchelt, D. R., Price, D. L., et al. (1997) · Neuron · doi:10.1016/s0896-6273(00)80272-x · Cited by 1,341 · cited 2×
“Following that initial study with the G93A variant, 13 additional transgenic mice have been made that produced a broad range of outcomes but all exhibit some characteristics of the disease (Ripps et al. 1995; Wong et al. 1995; Bruijn et al. 1997; Wang et al. 2002, 2003, 2005b; Tobisawa et al. 2003; Jonsson et al. 2004…”
MethodNeuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein
Giasson, B. I., Duda, J. E., Quinn, S. M., Zhang, B., Trojanowski, J. Q., & Lee, V. M.-Y. (2002) · Neuron · doi:10.1016/s0896-6273(02)00682-7 · Cited by 1,266
Mutations of optineurin in amyotrophic lateral sclerosis
Maruyama, H., Morino, H., Ito, H., Izumi, Y., Kato, H., Watanabe, Y., Kinoshita, Y., Kamada, M., Nodera, H., Suzuki, H., et al. (2010) · Nature · doi:10.1038/nature08971 · Cited by 1,265
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity
West, A. B., Moore, D. J., Biskup, S., Bugayenko, A., Smith, W. W., Ross, C. A., Dawson, V. L., & Dawson, T. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507360102 · Cited by 1,228
A mutation in the Amyloid Precursor Protein Associated with Hereditary Alzheimer's Disease
Murrell, J., Farlow, M., Ghetti, B., & Benson, M. D. (1991) · Science · doi:10.1126/science.1925564 · Cited by 1,127
Mitochondrial Dysfunction and Oxidative Damage in parkin-deficient Mice
Palacino, J. J., Sagi, D., Goldberg, M. S., Krauss, S., Motz, C., Wacker, M., Klose, J., & Shen, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401135200 · Cited by 995
Zhang, Y., Gao, J., Chung, K. K. K., Huang, H., Dawson, V. L., & Dawson, T. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.240347797 · Cited by 982 · cited 1×
“Parkin has an E3 ubiquitin-protein ligase activity (Shimura et al. 2000) and targets proteins for degradation by the proteosome (Zhang et al. 2000; Chung et al. 2001; Imai et al. 2001).”
Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease
Oddo, S. (2003) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.08.012 · Cited by 980 · cited 4×
“The 3xTg-AD mice progressively develop synaptic dysfunction, APP-contain- ing plaques and NFTs (Oddo et al. 2003a, b).”
InfluentialParkin-deficient Mice Exhibit Nigrostriatal Deficits but Not Loss of Dopaminergic Neurons
Goldberg, M. S., Fleming, S. M., Palacino, J. J., Cepeda, C., Lam, H. A., Bhatnagar, A., Meloni, E. G., Wu, N., Ackerson, L. C., Klapstein, G. J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308947200 · Cited by 913 · cited 2×
“Several laboratories have generated parkin knockout mice by targeting different exons of the parkin gene (Bonifati et al. 2003; Goldberg et al. 2003; Palacino et al. 2004; Von Coelln et al. 2004; Perez et al. 2005; Sato et al. 2006).”
Chung, K. K. K., Zhang, Y., Lim, K. L., Tanaka, Y., Huang, H., Gao, J., Ross, C. A., Dawson, V. L., & Dawson, T. M. (2001) · Nature Medicine · doi:10.1038/nm1001-1144 · Cited by 750 · cited 1×
“Parkin has an E3 ubiquitin-protein ligase activity (Shimura et al. 2000) and targets proteins for degradation by the proteosome (Zhang et al. 2000; Chung et al. 2001; Imai et al. 2001).”
Yang, Y., Hentati, A., Deng, H.-X., Dabbagh, O., Sasaki, T., Hirano, M., Hung, W.-Y., Ouahchi, K., Yan, J., Azim, A. C., et al. (2001) · Nature Genetics · doi:10.1038/ng1001-160 · Cited by 743
Van Deerlin, V. M., Leverenz, J. B., Bekris, L. M., Bird, T. D., Yuan, W., Elman, L. B., Clay, D., Wood, E. M., Chen-Plotkin, A. S., Martinez-Lage, M., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70071-1 · Cited by 723
The genetic epidemiology of neurodegenerative disease
Bertram, L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24761 · Cited by 680 · cited 2×
“Although APOE-E4 remains the highest risk factor identified for sporadic AD (Bertram and Tanzi 2005), no transgenic animals based on APOE-E4 allele have produced an AD phenotype.”
Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons
Ekstrand, M. I., Terzioglu, M., Galter, D., Zhu, S., Hofstetter, C., Lindqvist, E., Thams, S., Bergstrand, A., Hansson, F. S., Trifunovic, A., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605208103 · Cited by 605 · cited 2×
“HEK-293T cells transfected with the R1441C/G mutant of LRRK2 had decreased GTPase activity compared to non-mutant LRRK2 (Ekstrand et al. 2007).”
Self-citationLinking Aβ and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis
Small, S. A., & Duff, K. (2008) · Neuron · doi:10.1016/j.neuron.2008.11.007 · Cited by 546 · cited 2×
“…synaptic transmission and reduction in dendritic density and complexity (Wang et al. 2005a; Dumanis et al. 2009), There is also strong evidence that APOE-E4 increases deposition of Ab peptide in amyloid plaques and evidence that APOE can influence tau phosphorylation (Small and Duff 2008).”
Cha, J.-H. J., Kosinski, C. M., Kerner, J. A., Alsdorf, S. A., Mangiarini, L., Davies, S. W., Penney, J. B., Bates, G. P., & Young, A. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6480 · Cited by 504
Neuron loss in APP transgenic mice
Calhoun, M. E., Wiederhold, K.-H., Abramowski, D., Phinney, A. L., Probst, A., Sturchler-Pierrat, C., Staufenbiel, M., Sommer, B., & Jucker, M. (1998) · Nature · doi:10.1038/27351 · Cited by 502 · cited 1×
“Similar to Tg2576, the APP23 developed plaques, around 6 months of age, and had cerebrovascular amyloid and some neuronal loss (Sturchler-Pierrat et al. 1997; Calhoun et al. 1998, 1999).”
Clark, R. F., Hutton, M., Fuldner, M., Froelich, S., Karran, E., Talbot, C., Crook, R., Lendon, C., Prihar, G., He, C., et al. (1995) · Nature Genetics · doi:10.1038/ng1095-219 · Cited by 474
Calhoun, M. E., Burgermeister, P., Phinney, A. L., Stalder, M., Tolnay, M., Wiederhold, K.-H., Abramowski, D., Sturchler-Pierrat, C., Sommer, B., Staufenbiel, M., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.24.14088 · Cited by 410 · cited 1×
“Similar to Tg2576, the APP23 developed plaques, around 6 months of age, and had cerebrovascular amyloid and some neuronal loss (Sturchler-Pierrat et al. 1997; Calhoun et al. 1998, 1999).”
Deleterious Variants of FIG4, a Phosphoinositide Phosphatase, in Patients with ALS
Chow, C. Y., Landers, J. E., Bergren, S. K., Sapp, P. C., Grant, A. E., Jones, J. M., Everett, L., Lenk, G. M., McKenna-Yasek, D. M., Weisman, L. S., et al. (2009) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.12.010 · Cited by 407
Herzig, M. C., Winkler, D. T., Burgermeister, P., Pfeifer, M., Kohler, E., Schmidt, S. D., Danner, S., Abramowski, D., Stürchler-Pierrat, C., Bürki, K., et al. (2004) · Nature Neuroscience · doi:10.1038/nn1302 · Cited by 391 · cited 2×
“The E693Q mutant form of APP was used to generate the APP-Dutch transgenic mouse which developed congophilic amyloid angiopathy, but did not show other phenotypes consistent with AD (Herzig et al. 2004).”
Raber, J., Wong, D., Buttini, M., Orth, M., Bellosta, S., Pitas, R. E., Mahley, R. W., & Mucke, L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10914 · Cited by 364 · cited 2×
“However, replacement of the mouse APOE gene with human APOE4 allele causes cognitive impairments (Raber et al. 1998), decreased excitatory synaptic transmission and reduction in dendritic density and complexity (Wang et al. 2005a; Dumanis et al. 2009), There is also strong evidence that…”
Genetic aspects of Alzheimer disease.
Bird, T. D. (2008) · Genetics in Medicine · doi:10.1097/gim.0b013e31816b64dc · Cited by 356
Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis
Kraemer, B. C., Schuck, T., Wheeler, J. M., Robinson, L. C., Trojanowski, J. Q., Lee, V. M. Y., & Schellenberg, G. D. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0659-0 · Cited by 350 · cited 2×
“/-) mice exhibit signs of motor defects and muscle weakness (Kraemer et al. 2010).”
PINK1 protein in normal human brain and Parkinson's disease
Gandhi, S. (2006) · Brain · doi:10.1093/brain/awl114 · Cited by 342 · cited 4×
“PINK1 is present throughout the brain and localizes to mitochondria where it is thought to protect against mitochondrial dysfunction (Gandhi et al. 2006).”
InfluentialA decade of modeling Alzheimer's disease in transgenic mice
MCGOWAN, E., ERIKSEN, J., & HUTTON, M. (2006) · Trends in Genetics · doi:10.1016/j.tig.2006.03.007 · Cited by 287 · cited 4×
“There have been several transgenic mice generated based on mutations in the human MAPT gene that have provided clear evidence for mutant tau in NFT pathology and dementia (McGowan et al. 2006).”
InfluentialBehavioral and Neurochemical Effects of Wild-Type and Mutated Human α-Synuclein in Transgenic Mice
Richfield, E. K., Thiruchelvam, M. J., Cory-Slechta, D. A., Wuertzer, C., Gainetdinov, R. R., Caron, M. G., Di Monte, D. A., & Federoff, H. J. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.7882 · Cited by 285 · cited 6×
“2001), mice expressing wild-type or doublemutant human a-synuclein were more susceptible to MPTP toxicity (Richfield et al. 2002).”
InfluentialMatsuoka, Y., Vila, M., Lincoln, S., McCormack, A., Picciano, M., LaFrancois, J., Yu, X., Dickson, D., Langston, W. J., McGowan, E., et al. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0392 · Cited by 281 · cited 3×
“…a full phenocopy of PD. Selective expression of the wild-type, A53T or A30P mutants in dopaminergic neurons using the tyrosine hydroxylase promoter did not cause selective loss of nigral neurons or striatal dopamine, or the development of inclusions in dopaminergic neurons (Matsuoka et al. 2001).”
InfluentialHuman APOE Isoform-Dependent Effects on Brain β-Amyloid Levels in PDAPP Transgenic Mice
Bales, K. R., Liu, F., Wu, S., Lin, S., Koger, D., DeLong, C., Hansen, J. C., Sullivan, P. M., & Paul, S. M. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.0887-09.2009 · Cited by 274 · cited 2×
“Mice expressing human APOE4 allele in a mouse APOE4 null background exhibited increased insoluble APOE protein in parallel with an increased Ab burden as they aged (Bales et al. 2009).”
ApoE4 Decreases Spine Density and Dendritic Complexity in Cortical Neurons In Vivo
Dumanis, S. B., Tesoriero, J. A., Babus, L. W., Nguyen, M. T., Trotter, J. H., Ladu, M. J., Weeber, E. J., Turner, R. S., Xu, B., Rebeck, G. W., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4026-09.2009 · Cited by 220 · cited 2×
“excitatory synaptic transmission and reduction in dendritic density and complexity (Wang et al. 2005a; Dumanis et al. 2009), There is also strong evidence that APOE-E4 increases deposition of Ab peptide in amyloid plaques and evidence that APOE can influence tau phosphorylation (Small and Duff 2008).”
Human apoE4-targeted replacement mice display synaptic deficits in the absence of neuropathology.
Wang, C., Wilson, W. A., Moore, S. D., Mace, B. E., Maeda, N., Schmechel, D. E., & Sullivan, P. M. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.10.013 · Cited by 138
Rathke‐Hartlieb, S., Kahle, P. J., Neumann, M., Ozmen, L., Haid, S., Okochi, M., Haass, C., & Schulz, J. B. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00366.x · Cited by 128 · cited 1×
“A separate study by Rathke-Hartlieb et al. (2001) showed similar findings and reported no change in sensitivity to the dopaminergic toxin, MPTP. Richfield et al. (2002) used the rat tyrosine hydroxylase 9.0 kb promoter to express a transgenic double mutant (A53T and A30P) form of a-synuclein in…”
InfluentialTau Aggregation and Toxicity in Tauopathic Neurodegenerative Diseases
Honson, N. S., & Kuret, J. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-14409 · Cited by 54
Hyperphosphorylated tau is a cause of neuronal dysfunction in tauopathy
Takashima, A. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14403 · Cited by 40 · cited 2×
“A major component of the NFTs is MAPT and changes in its phosphorylation, cellular distribution, and structure can lead to tau pathologies or ‘‘tauopathies’’ such as that seen in AD (Brunden et al. 2008; Garcia-Sierra et al. 2008; Honson and Kuret 2008; Takashima 2008).”
Cited by
A Progressive Mouse Model of Parkinson’s Disease: The Thy1-aSyn (“Line 61”) Mice
Chesselet, M.-F., Richter, F., Zhu, C., Magen, I., Watson, M. B., & Subramaniam, S. R. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0104-2 · Cited by 346
“For clarity, the present report will focus on findings in this model because extensive descriptions of other alpha-synuclein over-expressing mice have been recently published by us and other groups [17–20].”
MethodEffects of natural antioxidants in neurodegenerative disease
Albarracin, S. L., Stab, B., Casas, Z., Sutachan, J. J., Samudio, I., Gonzalez, J., Gonzalo, L., Capani, F., Morales, L., & Barreto, G. E. (2012) · Nutritional Neuroscience · doi:10.1179/1476830511y.0000000028 · Cited by 271
Astrocytes as a Source for Extracellular Matrix Molecules and Cytokines
Wiese, S., Karus, M., & Faissner, A. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00120 · Cited by 262
“Astrocytes are involved in various neurodegenerative diseases, including Alzheimer’s disease (AD), PD, and amyotrophic lateral sclerosis (ALS; Harvey et al., 2010).”
BackgroundThe advent of AAV9 expands applications for brain and spinal cord gene delivery
Dayton, R. D., Wang, D. B., & Klein, R. L. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.681463 · Cited by 144
Insights on the Use of Transgenic Mice Models in Alzheimer’s Disease Research
Pádua, M. S., Guil-Guerrero, J. L., Prates, J. A. M., & Lopes, P. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052805 · Cited by 46
Metadata
- Authors
- Harvey, B. K., Richie, C. T., Hoffer, B. J., & Airavaara, M.
- Venue
- Journal of Neural Transmission
- Published
- 2010-10-08
- Volume
- 118
- Issue
- 1
- Pages
- 27-45
- ISSN
- 0300-9564 (ISSN-L)
- 1435-1463
- OpenAlex
- W2142768713
- Cited by
- 39
- References
- 43
- FWCI
- 3.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.